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Effects of a Single Intra-Articular Injection of a
Microsphere Formulation of Triamcinolone
Acetonide on Knee Osteoarthritis Pain
A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study
Philip G. Conaghan, MBBS, PhD, FRACP, FRCP, David J. Hunter, MBBS, PhD, FRACP, Stanley B. Cohen, MD,
Virginia B. Kraus, MD, PhD, Francis Berenbaum, MD, PhD, Jay R. Lieberman, MD, Deryk G. Jones, MD, Andrew I. Spitzer, MD,
David S. Jevsevar, MD, MBA, Nathaniel P. Katz, MD, MS, Diane J. Burgess, PhD, Joelle Lufkin, MPH, James R. Johnson, PhD, and
Neil Bodick, MD, PhD, on behalf of the FX006-2014-008 Participating Investigators
Background: Intra-articular corticosteroids relieve osteoarthritis pain, but rapid systemic absorption limits efﬁcacy.
FX006, a novel, microsphere-based, extended-release triamcinolone acetonide (TA) formulation, prolongs TA joint resi-
dence and reduces systemic exposure compared with standard TA crystalline suspension (TAcs). We assessed symp-
tomatic beneﬁts and safety of FX006 compared with saline-solution placebo and TAcs.
Methods: In this Phase-3, multicenter, double-blinded, 24-week study, adults ‡40 years of age with knee osteoarthritis
(Kellgren-Lawrence grade 2 or 3) and average-daily-pain (ADP)-intensity scores of ‡5 and £9 (0 to 10 numeric rating scale)
were centrally randomized (1:1:1) to a single intra-articular injection of FX006 (32 mg), saline-solution placebo, or TAcs
(40 mg). The primary end point was change from baseline to week 12 in weekly mean ADP-intensity scores for FX006
compared with saline-solution placebo. Secondary end points were area-under-effect (AUE) curves of the change in weekly
mean ADP-intensity scores from baseline to week 12 for FX006 compared with saline-solution placebo, AUE curves of the
change in weekly mean ADP-intensity scores from baseline to week 12 for FX006 compared with TAcs, change in weekly
mean ADP-intensity scores from baseline to week 12 for FX006 compared with TAcs, and AUE curves of the change in
weekly mean ADP-intensity scores from baseline to week 24 for FX006 compared with saline-solution placebo. Exploratory
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end points included week-12 changes in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and
Knee Injury and Osteoarthritis Outcome Score Quality of Life (KOOS-QOL) subscale scores for FX006 compared with
saline-solution placebo and TAcs. Adverse events were elicited at each inpatient visit.
Results: The primary end point wasmet. Among 484 treated patients (n = 161 for FX006, n = 162 for saline-solution placebo,
and n= 161 for TAcs), FX006provided signiﬁcant week-12 improvement in ADP intensity comparedwith that observed for saline-
solution placebo (least-squaresmean change frombaseline:23.12 versus22.14; p < 0.0001) indicating;50% improvement.
FX006 afforded improvements over saline-solution placebo for all secondary and exploratory end points (p < 0.05). Improve-
ments in osteoarthritis pain were not signiﬁcant for FX006 compared with TAcs using the ADP-based secondary measures.
Exploratory analyses ofWOMAC-A, B, and C and KOOS-QOL subscales favored FX006 (p £ 0.05). Adverse events were generally
mild, occurring at similar frequencies across treatments.
Conclusions: FX006 provided signiﬁcant, clinically meaningful pain reduction compared with saline-solution placebo at
week 12 (primary end point).
Level of Evidence: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.
I
n 1955, intra-articular injection of corticosteroids (par-
ticularly hydrocortisone acetate) was reported to be effec-
tive in 80% of arthritic joints, but the transitory nature of
the effect “limited its practical value as a therapy.”1 Subse-
quently, more potent synthetic corticosteroids replaced hy-
drocortisone for intra-articular indications; controlled clinical
studies of these analogs also demonstrated short-term effects2,3.
Pharmacokinetic study indicated the efﬂux of corticosteroids
from the joint within hours of injection4.
Osteoarthritic pain represents a major health problem for
aging and increasingly obese populations5. Modern evidence-
based management guidelines from the American Academy of
Orthopaedic Surgeons (AAOS) and the American College of
Rheumatology (ACR) recommend a combination of pharma-
cological and non-pharmacological therapies, including joint
replacement6,7. In practice, the utility of oral pharmacotherapy is
limited by modest efﬁcacy and side effects6,8,9, and the treatment
effect of intra-articular hyaluronic acid preparations has been
questioned6,10,11. Despite the short-term efﬁcacy, and perhaps
reﬂecting the paucity of effective alternatives, intra-articular
corticosteroid use is common. Among beneﬁciaries with knee
osteoarthritis identiﬁed from a 1999 to 2013Medicare 5% sample,
>25% of the nearly 12 million people with knee osteoarthritis
received intra-articular corticosteroid injections; the fraction of
newly diagnosed knee patients receiving intra-articular cortico-
steroids increased from 0.27 to 0.45 during the time period12.
FX006 is a novel, microsphere-based, extended-release
formulation of triamcinolone acetonide (TA) for intra-articular
injection. Within each 35-to-55-mm microsphere, small (<5
mm) TA crystals are embedded in a poly(lactic-co-glycolic acid)
(PLGA) matrix (Fig. 1-A). Pharmacokinetic assessments have
demonstrated that measurable TA concentrations persist in the
joint for ‡12 weeks13, indicative of long duration of release as
compared with other marketed PLGA small-molecule formu-
lations14. Typically, PLGA microspheres exhibit a triphasic drug-
release proﬁle, with an initial burst, a subsequent lag phase with
minimal drug release, and a zero-order-release phase via bulk
polymer erosion15-18. In vitro, FX006 does not exhibit a burst or lag
phase; rather, release commences immediately and is continuous
(data on ﬁle). In the early-release phase, scanning electron mi-
croscopy reveals small channels approximately 500 nm in di-
ameter on the smooth, largely intact, microsphere surface (Fig.
1-B). These nanochannels are unique to FX006 and presumably
limit both TA egress from the microsphere’s interior and poly-
mer hydration, slowing bulk erosion and prolonging drug re-
lease. PLGA is degraded to oligomeric poly-acid units and then
to lactic and glycolic acids19, followed by elimination as carbon
dioxide and water.
In a rat model of localized synovitis, FX006 was demon-
strated to signiﬁcantly (p < 0.05 versus vehicle control) reduce
pain as assessed by gait scores, with a prolonged effect relative to
standard TA crystalline suspension (TAcs); signiﬁcantly im-
proved (p < 0.05 versus vehicle control) histological joint scores
were observed with effective doses of FX006 but not with TAcs20.
In a clinical study, peak plasma TA concentrations following
intra-articular injection in patients with knee osteoarthritis were
approximately 11 times lower following the proposed clinical
dose of FX006 compared with 40 mg (the routine clinical dose)
of TAcs; measurable intra-articular TA concentrations were
observed for ‡12 weeks13. In Phase-2 testing, FX006 adminis-
tered at the proposed clinical dose produced statistically signif-
icant improvements in osteoarthritis average-daily-pain (ADP)
intensity as compared with TAcs 40 mg (weeks 5 to 10)21, and
provided meaningful diminution of pain intensity, with maxi-
mal effects observed at week 5 and persisting through week 13,
compared with saline-solution placebo22.
In this article, we describe a Phase-3, randomized con-
trolled trial comparing FX006 with saline-solution placebo,
primarily, and TAcs, secondarily, with respect to efﬁcacy and
safety in patients with knee osteoarthritis.
Materials and Methods
Trial Design
In this Phase-3, double-blinded, multinational study (41global sites), participants were centrally randomized
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(1:1:1, block size = 6; FlexRandomizer [Cytel], with stratiﬁ-
cation by baseline weekly ADP-intensity score [5 to <6, 6 to
<7, or ‡7]) to receive a single intra-articular injection of
FX006 (32 mg), saline-solution placebo, or a routine dose
(40 mg) of TAcs. Patients with bilateral disease designated the
more painful knee as the index knee at screening. Following
informed consent, analgesic medications for index-knee pain
were withheld, with the exception of acetaminophen or
paracetamol (£3,000 mg/day; 500-mg tablets provided as
rescue treatment). For details of study blinding, see the
Appendix.
This study was registered at clinicaltrials.gov (NCT02357459).
Patients were evaluated at 7 outpatient visits (day
1 [baseline] and weeks 4, 8, 12, 16, 20, and 24). ADP intensity
was assessed daily (4:00 P.M. to 12:00 A.M. locally) via an in-
teractive voice-response system. Patients reported pain in-
tensity according to a numeric rating scale (NRS; with 0
indicating no pain and 10 indicating pain “as bad as you can
imagine”)23,24. The Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) Likert 3.1, 5-point
subscales, with higher scores indicating worse status,25 were
employed to assess pain (WOMAC-A), stiffness (WOMAC-
B), and physical function (WOMAC-C). The Knee Injury
and Osteoarthritis Outcome Score was used to assess quality
of life (KOOS-QOL; 0 to 4 Likert scale, with a higher
score indicating better quality of life)26. Both instruments
were administered as local language-validated question-
naires (see Appendix). Patients recorded rescue medication
use daily via an interactive voice-response system and re-
turned medication bottles at study visits. For additional
details regarding index-knee radiographic assessment, mea-
surement instruments, and adverse events (AEs), see the
Appendix.
Participants
Institutional review board approval was obtained from all
study sites. Eligible patients who provided signed informed
consent (n = 486) were enrolled and randomized at 38
centers in North America (United States and Canada),
Australia and New Zealand, Asia (Hong Kong), and the
European Union; 484 patients were treated (Fig. 2). Eligible
for inclusion were men and women ‡40 years of age with
symptomatic knee osteoarthritis per ACR criteria27 for
‡6 months prior to screening, Kellgren-Lawrence grade-2 or
328 osteoarthritis in the index knee as assessed on the
screening radiograph, patient-reported pain for >15 days in
the previous month, and a 24-hour ADP-intensity score of
‡5 and £923,24 for ‡5 days during the week preceding ran-
domization and intra-articular injection. For the exclusion
criteria, see the Appendix.
Interventions
Patients received a single intra-articular injection of FX006
(5 mL injection volume), saline-solution placebo (5 mL), or
TAcs 40 mg (1 mL), allowing comparisons between FX006
and a current standard of care. FX006 was supplied as a sterile
powder for reconstitution; dose-delivery studies indicate that
this provides an injection of 32 mg of TA into the joint. For
additional details of the study agents and administration, see
the Appendix.
Outcomes of Interest and Statistical Methods
The primary outcome, the least-squares mean (LSM) change
from baseline to week 12 in weekly mean ADP-intensity scores
for FX006 compared with saline-solution placebo in the full
analysis set (the randomized and treated patients), was ana-
lyzed with a longitudinal mixed-effects model for repeat
measures using observed data, with ﬁxed effects for treatment
group, study week, treatment-by-week interaction, study site,
and baseline pain, and a random patient effect. The SAS/STAT
PROC MIXED procedure (2015; SAS Institute) employed
an unstructured correlation matrix to model within-patient
error. For additional details of the sensitivity analyses, see the
Appendix.
Fig. 1
Figs. 1-A and 1-B FX006, an intra-articular extended-release formulation of triamcinolone acetonide (TA). Fig. 1-A Raman image of microsphere cross-
sections. Within each microsphere, small crystals of TA (red) are embedded in a poly(lactic-co-glycolic acid) matrix (green). Fig. 1-B Scanning electron
microscopy (SEM) imageof amicrosphere collected in the initial phaseof release. Small channelsapproximately 500nm in diameter appearon thesmooth,
largely intact surface of the microsphere.
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Secondary end points were area-under-effect (AUE)
curves of the change in weekly mean ADP-intensity scores
from baseline to week 12 (AUEweek1-12) for FX006 compared
with saline-solution placebo, AUEweek1-12 for FX006 com-
pared with TAcs, change in weekly mean ADP-intensity scores
from baseline to week 12 for FX006 compared with TAcs, and
AUE curves of the change in weekly mean ADP-intensity
scores from baseline to week 24 for FX006 compared with
saline-solution placebo (AUEweek1-24). In the step-down
testing procedure29 implemented for primary and secondary
end points, sequential testing proceeded as long as p < 0.05. P
values resulting from testing conducted after the ﬁrst non-
signiﬁcant p value were considered informative only. Changes
to secondary end points and sequential testing order during
development of the Statistical Analysis Plan after trial initia-
tion were made blinded to any clinical data and results (see the
Appendix).
Analyses conducted for the secondary end points out-
lined above and additional exploratory end points (changes in
WOMAC and KOOS-QOL scores, changes in ADP-intensity
scores at additional time points, >30% and >50% improve-
ment in ADP-intensity scores, and rescue medication use)
utilized models similar to primary end-point analyses for
outcomes involving score changes, summarization of “time-to-
event” weekly mean ADP-intensity scores via Kaplan-Meier
methodology, and calculation of AUE curves for ADP-intensity
score changes over time using linear trapezoidal methodology.
The proportions of patients achieving >30% and >50% im-
provement in ADP-intensity scores were compared using a
logistic regression model with study site as a covariate. The
Fig. 2
FX006 Phase-3 study in knee osteoarthritis: patient disposition through week 24. TAcs = triamcinolone acetonide crystalline suspension, and placebo =
saline-solution placebo.
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mean number of daily rescue medication tablets per week was
summarized.
For sample size determination, see the Appendix.
Results
Participant Flow and Baseline Characteristics
The study was conducted at 41 sites from January 29, 2015to January 21, 2016. Among the 486 patients enrolled over
6 months by 38 sites and randomized to FX006 (n = 161),
saline-solution placebo (n = 163), or TAcs (n = 162), 2 patients
(1 in the saline-solution placebo group and 1 in the TAcs
group) were neither treated nor included in the full analysis set
or safety populations. Overall, 443 (91.2%) of the patients
completed the study through week 24, and 43 (8.8%) dis-
continued prematurely (n = 17, 14, and 12 across the respective
treatment arms; from 21 [55.3%] of the 38 enrolling study sites;
TABLE I Baseline Patient Characteristics and Baseline Values for Outcome Measures*
Parameter
Treatment Group
Total, N = 484FX006, N = 161
Saline-Solution
Placebo, N = 162 TAcs, N = 161
Female (no. [%]) 103 (64.0) 96 (59.3) 97 (60.2) 296 (61.2)
White (no. [%]) 130 (80.7) 144 (88.9) 131 (81.4) 405 (83.7)
Age at consent† (yr) 61.5 ± 9.52 62.4 ± 8.89 62.3 ± 10.08 62.1 ± 9.49
BMI† (kg/m2) 30.1 ± 5.01 30.2 ± 4.69 30.3 ± 4.82 30.2 ± 4.83
BMI category (no. [%])
Normal (18.5-24.9 kg/m2) 28 (17.4) 22 (13.6) 25 (15.5) 75 (15.5)
Overweight (25.0-29.9 kg/m2) 57 (35.4) 58 (35.8) 53 (32.9) 168 (34.7)
Class-I obese (30.0-34.9 kg/m2) 45 (28.0) 52 (32.1) 55 (34.2) 152 (31.4)
Class-II obese (35.0-39.9 kg/m2) 31 (19.3) 30 (18.5) 28 (17.4) 89 (18.4)
Type of knee osteoarthritis (no. [%])
Unilateral 51 (31.7) 60 (37.0) 59 (36.6) 170 (35.1)
Bilateral 110 (68.3) 102 (63.0) 102 (63.4) 314 (64.9)
No. of yr since diagnosis† 7.6 ± 6.56 6.6 ± 5.79 7.5 ± 6.70 7.2 ± 6.37
No. of days with index-knee pain
in past month†
28.4 ± 3.86 28.3 ± 3.80 28.0 ± 4.18 28.2 ± 3.95
Kellgren-Lawrence grade (no. [%])
2 79 (49.1) 69 (42.6) 69 (42.9) 217 (44.8)
3 82 (50.9) 93 (57.4) 91 (56.5) 266 (55.0)
4 0 0 1 (0.6)‡ 1 (0.2)‡
ADP-intensity score (0-10)† 6.3 ± 0.93 6.3 ± 0.98 6.3 ± 0.90 6.3 ± 0.94
Weekly ADP-intensity score (0-10)
category§ (no. [%])
5 to <6 68 (42.2) 68 (42.0) 68 (42.2) 204 (42.1)
6 to <7 52 (32.3) 52 (32.1) 51 (31.7) 155 (32.0)
‡7 41 (25.5) 42 (25.9) 42 (26.1) 125 (25.8)
WOMAC score (0-4)†
A: pain 2.0 ± 0.53 2.0 ± 0.52 2.0 ± 0.52 2.0 ± 0.52
B: stiffness 2.3 ± 0.88 2.4 ± 0.79 2.3 ± 0.87 2.3 ± 0.85
C: physical function 2.1 ± 0.56 2.1 ± 0.51 2.1 ± 0.58 2.1 ± 0.55
KOOS-QOL (0-4)†# 29.9 ± 16.11 31.9 ± 16.64 31.8 ± 15.49 31.2 ± 16.09
*Full analysis set, N = 484. TAcs = triamcinolone acetonide crystalline suspension, BMI = bodymass index, ADP = average daily pain, WOMAC
= Western Ontario and McMaster Universities Osteoarthritis Index, and KOOS-QOL = Knee Injury and Osteoarthritis Outcome Score Quality of
Life. †The values are given as the mean and the standard deviation. ‡The patient with a Kellgren-Lawrence grade of 4, in violation of the
entrance criteria, was included in the full analysis set. §Randomization was stratiﬁed by baseline ADP-intensity score category. #Normalized
scores (100 indicating no symptoms and 0 indicating extreme symptoms) were calculated as: 1002AVERAGE(Q1-Q4)/4*100. The numbers
of patients with baseline KOOS-QOL assessments were 136, 144, 134, and 414 across the FX006, saline-solution placebo, TAcs, and total
groups, respectively.
670
THE JOURNAL OF BONE & JOINT SURGERY d J B J S .ORG
VOLUME 100-A d NUMBER 8 d APRIL 18, 2018
SINGLE IA IN JECT ION OF MICROSPHERE FORMULAT ION OF
TR IAMCINOLONE ACETONIDE ON KNEE OA PAIN
£5 of the patients from any site). Sixteen (3.3%) of the patients
(n = 5, 8, and 3 across the groups) discontinued before week 12
(Fig. 2).
The treatment groups were well balanced with respect to
baseline patient characteristics and values for outcome mea-
sures. Patients ranged from 40 to 85 years of age (mean, 62
years), the majority were female (61.2%), and approximately
50% were obese (body mass index of ‡30 kg/m2). The mean
number of years between the diagnosis of knee osteoarthritis
per the ACR criteria and the start of the study was 7.2 (Table I).
Efficacy
The primary efﬁcacy end point was met. ADP intensity was
signiﬁcantly improved among the patients treated with FX006
compared with those treated with saline-solution placebo
(LSM change in weekly mean ADP-intensity scores from
baseline to week 12:23.12 compared with22.14, respectively;
LSM difference [95% conﬁdence interval (CI)]: 20.98 [21.47
to 20.49]; p < 0.0001) (Fig. 3-A), indicating that FX006 af-
forded approximately 50% improvement over saline-solution
placebo. The results of prespeciﬁed sensitivity analyses allowing
Fig. 3
Figs. 3-A through 3-F Least-squares (LS)mean change frombaseline (BL) (and standard error [SE]) for the efﬁcacy end points of weeklymean average daily
pain (ADP)-intensity scores (0 to 10 on numeric rating scale) at week 12, the primary end point (n = 484) (Fig. 3-A); Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC)-A (pain), WOMAC-B (stiffness), andWOMAC-C (physical function) subscale scores (n = 484) (Figs. 3-B, 3-C, and
3-D); Knee Injury andOsteoarthritis OutcomeScore-Quality of Life (KOOS-QOL) subscale score (n=414) (Fig. 3-E); and rescuemedication (med) use (mean
number of daily rescue medication [500-mg] tablets per week; n = 484) over time in the full analysis set (Fig. 3-F). Primary and exploratory secondary end-
point analysesemployedan analysis of covariancewithmodel parameters for treatment and covariates of baseline pain-intensity score and study site. TAcs
= triamcinolone acetonide crystalline suspension, and placebo = saline-solution placebo.
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for missing-data imputation were consistent with those of our
primary analysis (Table II).
With respect to the protocol-deﬁned secondary end
points (Table III), we found that AUEweek1-12 was signiﬁcantly
greater for FX006 compared with saline-solution placebo (LSM
change: 2247.3 compared with 2145.3, respectively; LSM
difference:2102.0; p < 0.0001), indicating that FX006 afforded
nearly twice the time-averaged reduction in ADP intensity
through week 12 compared with saline-solution placebo.
Similar ﬁndings were observed for AUEweek1-24 (LSM change:
2432.5 for FX006 compared with 2297.0 for placebo; LSM
difference: 2135.5; p = 0.0002).
FX006 demonstrated efﬁcacy advantages over saline-
solution placebo for exploratory end points, as evidenced by
greater improvements in the WOMAC pain, stiffness, and
physical function and KOOS-QOL subscale scores at weeks 4,
8, and 12 (all p < 0.0001) (Table IV) (Figs. 3-B through 3-E).
Greater proportions of patients treated with FX006 compared
with saline-solution placebo achieved the >30% (67.3% com-
pared with 53.0% at week 12; p < 0.05 at weeks 1 to 13 among
24 weeks assessed) andmore stringent >50% (52.3% compared
with 37.1% at week 12; p < 0.05 at weeks 1 to 16 and week 18)
ADP-intensity score improvement criteria. Signiﬁcantly fewer
rescue medication tablets per week were used by patients
treated with FX006 compared with placebo overall (LSM dif-
ference [95% CI]:20.50 [20.78 to20.21]; p = 0.0006) and at
each of weeks 2 to 16, 19, and 20 (p £ 0.0269) (Fig. 3-F).
Differences between FX006 and TAcs in AUEweek1-12
(LSM change: 2247.3 for FX006 compared with 2231.9 for
TAcs; LSM difference: 215.3; p = 0.3827) and change from
baseline to week 12 in ADP-intensity score (LSM change:23.1
compared with22.9; LSM difference:20.26; p = 0.2964) were
not signiﬁcant (Table III).
FX006 performed more favorably than did TAcs with
respect to exploratory end points, as evidenced by greater
improvements in WOMAC subscale scores for pain (p £
0.0475), stiffness (p £ 0.0182), and physical function (p £
0.0111) and the KOOS-QOL subscale score (p £ 0.0256) at
weeks 4, 8, and 12 (Table IV) (Figs. 3-B through 3-E). No
signiﬁcant differences were observed between the propor-
tions of FX006 and TAcs-treated patients achieving >30% or
>50% improvement in ADP-intensity scores from baseline
(not shown). FX006 onset-of-action was similar to that of
TAcs: median (95% CI) days to >30% improvement in ADP
intensity, 4 (4 to 5) for FX006 and 3 (3 to 5) for TAcs (not
shown).
Safety
Overall, 55.3%, 53.1%, and 56.5% of the patients in the
FX006, saline-solution placebo, and TAcs treatment groups,
TABLE II Summary of Prespeciﬁed Sensitivity Analyses of LSM Change in Weekly Mean ADP-Intensity Scores at Week 12 (Primary End Point)*
Primary Analysis BLOCF/LOCF Sensitivity Multiple Imputation Sensitivity
LSM change from baseline (SE)
FX006 23.12 (0.20) 22.97 (0.22) 23.05 (0.22)
Saline-solution placebo 22.14 (0.20) 21.98 (0.22) 22.02 (0.22)
LSM difference, placebo vs. FX006 (95% CI) 20.98 (21.47, 20.49) 20.99 (21.51, 20.48) 21.03 (21.53, 20.52)
P value <0.0001 <0.0002 <0.0001
*Full analysis set, N = 484. LSM = least-squares mean; ADP = average daily pain; BLOCF = baseline observation carried forward, for data missing
due to patient discontinuation resulting from adverse event(s)/“other” reasons; LOCF = last observation carried forward, for data missing due to
patient discontinuation because of lack of efﬁcacy; SE = standard error; and CI = conﬁdence interval.
TABLE III Summary of Protocol-Deﬁned Secondary Efﬁcacy End Points*
Secondary End Point Comparison
LSM Change (SE)
LSM Difference
(95% CI) P ValueFX006, N = 161
Saline-Solution
Placebo, N = 162 TAcs, N = 161
1. AUEweek 1-12 FX006 vs. placebo 2247.3 (14.89) 2145.3 (14.77) — 2102.0 (2136.8, 267.3) <0.0001
2. AUEweek 1-12 FX006 vs. TAcs 2247.3 (14.89) — 2231.9 (14.85) 215.3 (249.8, 19.2) 0.3827
3. ADP change from
baseline to week 12
FX006 vs. TAcs 23.12 (0.203) — 22.86 (0.202) 20.26 (20.74, 0.23) 0.2964†
4. AUEweek 1-24 FX006 vs. placebo 2432.5 (30.14) 2297.0 (29.90) — 2135.5 (2205.9, 265.2) 0.0002†
*Full analysis set, N =484. LSM= least-squaresmean, SE= standard error, TAcs= triamcinolone acetonide crystalline suspension, CI = conﬁdence interval, AUE=area
under effect, and ADP = average daily pain. †P value derived from sequential testing conducted after a prior end-point treatment difference was ‡0.05.
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respectively, reported AEs (see Table V for the most common
AEs). Across treatments, most AEs were mild/moderate (grade
1 or 2), nonserious, and unrelated to the study agent.
Serious AEs occurred in 3.1%, 1.9%, and 2.5% of the
patients treated with FX006, saline-solution placebo, and TAcs,
respectively (Table V). Each type of serious AE occurred in only
1 patient; none was considered related to the study agent. No
FX006-treated patient and <1% of the placebo and TAcs-
treated patients discontinued because of an AE (Table V). No
deaths occurred.
Index knee-related AEs (new and clinically relevant or
worsened index-knee ﬁndings), most of which were grade 1 or
2, nonserious, and unrelated to the study agent, occurred in
18.6%, 12.3%, and 9.9% of the patients treated with FX006,
saline-solution placebo, and TAcs, respectively (Table V). Most
index knee-related AEs occurred after day 3; none was con-
sistent with post-injection ﬂare.
Among the patients with baseline and week-24 index-
knee radiographs, worsening of joint-space narrowing was
uncommon, occurring in 7 (5.0%) of 140, 6 (4.1%) of 148, and
5 (3.5%) of 145 patients who received FX006, saline-solution
placebo, and TAcs, respectively. Joint-space narrowing wors-
ened by only 1 grade in these patients, with the exception of
1 patient treated with saline-solution placebo, who demon-
strated worsening from grade 0 to grade 2. One patient treated
with TAcs had an insufﬁciency fracture noted at week 24. No
subchondral bone change, osteonecrosis, or radiographically
documented rapidly progressive osteoarthritis was identiﬁed in
the patients treated with FX006. One FX006-treated patient
underwent uneventful total knee arthroplasty in the treated
knee on day 145. At the time of surgery, the patient’s ADP-
intensity score had improved from baseline, and the pre-
operative knee radiograph showed no change from baseline
(Kellgren-Lawrence grade 3).
No joint infections occurred. Non-joint infections occurred
in 16.8%, 19.1%, and 21.7% of the patients treated with FX006,
placebo, and TAcs, respectively; upper-respiratory tract infection,
nasopharyngitis, inﬂuenza, sinusitis, and viral upper-respiratory
tract infections were common across the groups. Hypertension
occurred in 3.1%, 3.7%, and 0% of the patients who received
FX006, saline-solution placebo, and TAcs, respectively.
Discussion
In primary analyses, a single intra-articular injection ofFX006 demonstrated statistically signiﬁcant reductions in
osteoarthritis pain intensity as compared with saline-solution
placebo. Secondary and exploratory analyses further evaluating
pain relief, function, and overall well-being consistently fa-
vored FX006 over saline-solution placebo. The FX006 analgesic
effect persisted for >12 weeks; onset of action was similar to
that of TAcs.
The improvements in osteoarthritis pain conferred by
FX006 are clinically relevant. Per accepted consensus crite-
ria specifying ‡50% improvement versus saline-solution
placebo as “substantial” for individual patients30, FX006
provided substantial improvements compared with saline-
solution placebo at weeks 1 to 16 and week 18 (p < 0.05). In a
separate analysis of data from the current study, the LSM
improvement afforded by FX006 compared with saline-
solution placebo at weeks 4, 8, and 12 exceeded the mini-
mally clinically important improvement thresholds for the
WOMAC pain, stiffness, and physical-function subscales
TABLE IV Summary of Prespeciﬁed Exploratory Efﬁcacy End Points*
Exploratory End Point Week
FX006 Vs. Saline-Solution Placebo FX006 Vs. TAcs
LSM Difference (95% CI) P Value LSM Difference (95% CI) P Value
WOMAC-A (pain) 4 20.60 (20.76, 20.44) <0.0001 20.23 (20.39, 20.07) 0.0052
8 20.54 (20.71, 20.37) <0.0001 20.21 (20.38, 20.04) 0.0158
12 20.37 (20.55, 20.20) <0.0001 20.17 (20.34, 20.00) 0.0475
WOMAC-B (stiffness) 4 20.72 (20.91, 20.53) <0.0001 20.23 (20.42, 20.04) 0.0179
8 20.69 (20.88, 20.50) <0.0001 20.32 (20.51, 20.13) 0.0009
12 20.44 (20.63, 20.25) <0.0001 20.23 (20.42, 20.04) 0.0182
WOMAC-C (physical function) 4 20.60 (20.75, 20.44) <0.0001 20.24 (20.40, 20.08) 0.0029
8 20.56 (20.73, 20.40) <0.0001 20.29 (20.45, 20.12) 0.0007
12 20.38 (20.54, 20.21) <0.0001 20.22 (20.38, 20.05) 0.0111
KOOS-QOL† 4 14.57 (10.01, 19.12) <0.0001 7.90 (3.29, 12.52) 0.0008
8 12.60 (8.02, 17.18) <0.0001 5.28 (0.65, 9.91) 0.0256
12 8.97 (4.37, 13.57) <0.0001 5.42 (0.78, 10.06) 0.0222
*Full analysis set, n = 484 (n = 414 for Knee Injury and Osteoarthritis Outcome Score Quality of Life [KOOS-QOL]). TAcs = triamcinolone acetonide
crystalline suspension, LSM = least-squares mean, CI = conﬁdence interval, and WOMAC = Western Ontario and McMaster Universities Osteo-
arthritis Index. †Normalized scores (100 indicating no symptoms and 0 indicating extreme symptoms) were calculated as: 1002AVERAGE(Q1-
Q4)/4*100.
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utilized by the AAOS to assess the “clinical signiﬁcance” of
treatment effects6,31,32. Furthermore, the 95% CIs sur-
rounding the FX006-associated LSM improvement in all
WOMAC subscales at weeks 4 and 8 exceeded minimally
clinically important improvement thresholds deﬁned by the
AAOS for determining a “clinically signiﬁcant” effect6. In a
systematic review of pharmacological interventions for
symptomatic knee osteoarthritis, the AAOS concluded that
no currently available injectable intra-articular treatments
(including corticosteroids and hyaluronic acids) provided a
“clinically signiﬁcant” treatment effect6. While there is
support for10, and criticism of11, the AAOS criteria, they
represent a systematic approach to identifying clinically
meaningful improvements.
Although differences between FX006 and TAcs per
protocol-speciﬁed ADP-based secondary end points were not
signiﬁcant, FX006 was superior to TAcs on exploratory end
points (WOMAC pain, stiffness and physical function and
TABLE V Summary of Adverse Events (AEs) by Treatment Group*
Treatment Group
FX006, N = 161 Saline-Solution Placebo, N = 162 TAcs, N = 161
‡1 AE 89 (55.3) 86 (53.1) 91 (56.5)
‡1 common AE (>5% in any treatment
group)
Arthralgia (any joint) 23 (14.3) 20 (12.3) 12 (7.5)
Headache 14 (8.7) 13 (8.0) 15 (9.3)
Back pain 9 (5.6) 9 (5.6) 12 (7.5)
‡1 serious AE 5 (3.1) 3 (1.9) 4 (2.5)
‡1 AE leading to study discontinuation 0 1 (0.6)‡ 1 (0.6)
AEs by maximum severity†
Grade 1 37 (23.0) 33 (20.4) 40 (24.8)
Grade 2 45 (28.0) 48 (29.6) 47 (29.2)
Grade 3 6 (3.7) 5 (3.1) 4 (2.5)
Grade 4 1 (0.6) 0 0
AEs by maximum relationship to study
agent
Not related 69 (42.9) 77 (47.5) 78 (48.4)
Unlikely 10 (6.2) 6 (3.7) 9 (5.6)
Possibly, probably, or deﬁnitely related 10 (6.2) 3 (1.9) 4 (2.5)
‡1 index knee-related AE‡ 30 (18.6) 20 (12.3) 16 (9.9)
‡1 serious index knee-related AE 1 (0.6) 0 0
‡1 index knee-related AE leading to study
discontinuation
0 1 (0.6)§ 1 (0.6)
Index knee-related AEs by maximum
severity†
Grade 1 18 (11.2) 7 (4.3) 8 (5.0)
Grade 2 11 (6.8) 12 (7.4) 6 (3.7)
Grade 3 1 (0.6) 1 (0.6) 2 (1.2)
Index knee-related AEs by maximum
relationship to study agent
Not related 22 (13.7) 14 (8.6) 10 (6.2)
Unlikely 3 (1.9) 3 (1.9) 5 (3.1)
Possibly, probably, or deﬁnitely related 5 (3.1) 3 (1.9) 1 (0.6)
‡1 AE related to injection procedure 5 (3.1) 5 (3.1) 3 (1.9)
*Safety population, N = 484. The values are given as the number of patients, with the percentage in parentheses. TAcs = triamcinolone
acetonide crystalline suspension. †If a patient experienced >1 AE in a given category, that patient was counted only once in that category.
‡Any index-knee ﬁnding that was new and clinically relevant or had worsened from baseline. §AE was nonserious and unrelated to the
study agent.
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KOOS-QOL data) at weeks 4, 8, and 12 (Fig. 3). Regarding the
inconsistency between the 2 instruments in assessing pain, it is
noted that WOMAC pain is a multi-item tool purpose-built for
knee osteoarthritis, whereas the NRS is a single-item measure
used for numerous indications23-25. A meta-analysis reviewing
125 randomized controlled trials found greater responsiveness
for the WOMAC pain subscale compared with single-item
pain-intensity measures33.
FX006 demonstrated an acceptable safety proﬁle.
Most AEs across the groups were grade 1 or 2, nonserious,
and unrelated to the study drug or injection procedure.
Intramuscular delivery of PLGA microspheres is associated
with a foreign-body response19,34; in synovial tissues of dogs
receiving intra-articular FX006, this was demonstrated to be
mild, self-limiting, localized, reversible, and without de-
tectable clinical effect35. The Phase-3 clinical data are con-
sistent with a lack of a clinically relevant foreign-body
response, as a single intra-articular FX006 injection dem-
onstrated systemic and local safety proﬁles generally similar
to those of saline-solution placebo and TAcs. Although the
numbers of FX006-treated patients to date are limited, the
time course of index knee-related AEs in this trial indicated
no post-injection ﬂares. Index knee-related arthralgia in the
FX006-treated patients was mild and occurred at time
points when patients still exhibited improved ADP-intensity
scores.
Early case reports associated joint damage with repeated
corticosteroid injections36,37. However, ﬁnal data from 2 con-
trolled imaging studies designed to assess how multiple injec-
tions administered over 2 years impact cartilage structure
yielded conﬂicting results38,39. In this study, we found no ra-
diographic evidence of rapidly progressive osteoarthritis in
either active arm through 24 weeks.
FX006 has the potential to demonstrate cost-effectiveness
as a knee osteoarthritis therapy. In a preliminary evaluation of
results from this trial pooled with results from other randomized
trials of FX00621,22, observed WOMAC-based clinical beneﬁts of
FX006 translated into an increase in quality of life for patients
with knee osteoarthritis, demonstrated by an average quality-
adjusted-life-years gain per 6 months of 0.189. Employing a
hypothetical drug cost of $500 (USD), FX006 was determined to
be cost-effective, with incremental cost-effectiveness ratios
(ICERs) of <$5,000 versus either conventional care or diclo-
fenac. FX006 was the dominant approach compared with intra-
articular hyaluronic acid in a further ICER analysis40. Additional
studies are required to fully understand the cost-beneﬁt and
cost-effectiveness implications of managing osteoarthritis knee
pain with FX006.
This study had limitations, including differing injec-
tion volumes for FX006 and saline-solution placebo (5 mL)
versus TAcs (1 mL, as employed in clinical practice). The
study was powered to detect signiﬁcant differences in changes
in ADP-intensity scores between FX006 and saline-solution
placebo but not signiﬁcant differences in rapidly progressive
osteoarthritis deﬁned by joint-space narrowing or loss of
ﬁxed joint space width. Exclusion of diabetics with a hemo-
globin A1c level of >7.5% and the absence of fasting clinical
laboratory assessments limit any potential conclusions con-
cerning the effects of FX006 compared with TAcs on serum
glucose levels.
In summary, this randomized double-blinded trial
demonstrated sustained and clinically meaningful reductions
in pain in knee osteoarthritis following a single intra-articular
injection of a novel microsphere-based corticosteroid formu-
lation that prolongs TA residency in synovial tissues compared
with saline-solution placebo (primary outcome). No osteoar-
thritis ﬂare or important AE signals were observed. The ob-
served magnitude and persistence of pain-intensity reduction
suggest that FX006 may have a place in knee osteoarthritis
treatment paradigms.
Appendix
Additional details regarding blinding, exclusion criteria,
assessments, adverse events, interventions, and outcomes
and statistical methods, and a table describing changes made to
the study efﬁcacy outcomes during the development of the
Statistical Analysis Plan are available with the online version of
this article as a data supplement at jbjs.org (http://links.lww.
com/JBJS/E646). n
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